Latest Finance News

Page 14 of 564
Atlantic Lithium’s Scheme Booklet has been registered with ASIC, putting Huayou’s proposed US$210 million acquisition on the final stretch towards a shareholder vote. BDO backs the deal in the absence of a superior offer, but several regulatory and transaction conditions remain outstanding.
Maxwell Dee
Maxwell Dee
6 Nov 2026
Third Age Health will acquire 75% of New Zealand asbestos specialist Consultex Group for $3.75 million, adding a new Testing, Inspection & Compliance vertical. The deal will be funded through existing cash and bank debt, with settlement expected by 30 November 2026.
Victor Sage
Victor Sage
6 Nov 2026
QuickFee’s Q1 FY27 revenue held at A$4.2 million on a normalised basis, while US loan originations rose 15% and Australian transaction values slipped. The lender maintained FY27 EBTDA guidance at A$4.5 million to A$5.0 million despite lower net interest margins and softer SME conditions.
Claire Turing
Claire Turing
6 Nov 2026
Starpharma is targeting a December start for first-in-human testing of its lead DEP HER2-Lu radiopharmaceutical, subject to ethics approval, as it shifts decisively toward targeted oncology. The company also outlined stronger funding, majority ownership of Petalion’s FAP program and a proposed Chair transition at its 2026 AGM.
Ada Torres
Ada Torres
6 Nov 2026
Clinuvel has outlined a multi-year expansion from peptide therapeutics into polymers, long-acting injectables, devices and digital health, backed by A$220 million of planned FY2027-FY2030 spending. The strategy comes with a near-term setback: first patient treatment in the CUV107 vitiligo study has been delayed to February 2027.
Victor Sage
Victor Sage
6 Nov 2026
US Medicare has set a national outpatient payment of US$31,265 for Epiminder’s Minder System implant procedure from 1 January 2027, up 13% on the 2026 rate. The decision gives hospitals a defined reimbursement benchmark ahead of Epiminder’s planned US commercial launch.
Ada Torres
Ada Torres
6 Nov 2026
Jumbo Interactive delivered record FY26 earnings despite a weak Australian jackpot cycle and reaffirmed its FY27 targets. The company is also pursuing a conditional A$6.45 million acquisition in Ontario while preparing for a CFO transition.
Victor Sage
Victor Sage
6 Nov 2026
Avenira has raised $48.87 million through its rights issue and shortfall placement, with major shareholder Hebang among those taking up entitlements. Combined with $85 million of debt facilities, the company expects the funding to cover the direct shipping ore phase at Wonarah ahead of planned first shipment in the first half of 2027.
Maxwell Dee
Maxwell Dee
6 Nov 2026
Mayne Pharma will sell its international operations, including the Salisbury manufacturing site, to Evaris Pharma for $55.5 million in cash. The deal leaves the company focused entirely on its US Women’s Health, Dermatology and DistributeRx businesses, subject to ACCC approval.
Victor Sage
Victor Sage
6 Nov 2026
Ameren has raised its 2026 earnings guidance and set a 2027 target after third-quarter adjusted EPS rose 12% year on year. The US utility also outlined a US$38.1 billion infrastructure programme supporting projected rate-base growth through 2031.
Maxwell Dee
Maxwell Dee
6 Nov 2026
Macquarie Bank’s half-year profit fell 61% to A$1.42 billion after a prior-period A$2.448 billion asset-transfer gain dropped out of the comparison. Its core banking and markets divisions still grew, but credit charges rose and margins remained under pressure.
Victor Sage
Victor Sage
6 Nov 2026
Macquarie Group delivered a 50% rise in first-half profit to A$2.478 billion, with Commodities and Global Markets providing the standout contribution as market activity accelerated. The result also marks Shemara Wikramanayake’s final day as chief executive, with Greg Ward taking over from 7 November.
Claire Turing
Claire Turing
6 Nov 2026

Browse the archive

Full archive